186 related articles for article (PubMed ID: 15639784)
1. Misfolding promotes the ubiquitination of polyglutamine-expanded ataxin-3, the defective gene product in SCA3/MJD.
Jana NR; Nukina N
Neurotox Res; 2004; 6(7-8):523-33. PubMed ID: 15639784
[TBL] [Abstract][Full Text] [Related]
2. Evidence for proteasome involvement in polyglutamine disease: localization to nuclear inclusions in SCA3/MJD and suppression of polyglutamine aggregation in vitro.
Chai Y; Koppenhafer SL; Shoesmith SJ; Perez MK; Paulson HL
Hum Mol Genet; 1999 Apr; 8(4):673-82. PubMed ID: 10072437
[TBL] [Abstract][Full Text] [Related]
3. Ataxin-3 with an altered conformation that exposes the polyglutamine domain is associated with the nuclear matrix.
Perez MK; Paulson HL; Pittman RN
Hum Mol Genet; 1999 Dec; 8(13):2377-85. PubMed ID: 10556285
[TBL] [Abstract][Full Text] [Related]
4. Caspase-mediated proteolysis of the polyglutamine disease protein ataxin-3.
Berke SJ; Schmied FA; Brunt ER; Ellerby LM; Paulson HL
J Neurochem; 2004 May; 89(4):908-18. PubMed ID: 15140190
[TBL] [Abstract][Full Text] [Related]
5. Expression of expanded polyglutamine protein induces behavioral changes in Drosophila (polyglutamine-induced changes in Drosophila).
Kim YT; Shin SM; Lee WY; Kim GM; Jin DK
Cell Mol Neurobiol; 2004 Feb; 24(1):109-22. PubMed ID: 15049515
[TBL] [Abstract][Full Text] [Related]
6. Ataxin-3 is translocated into the nucleus for the formation of intranuclear inclusions in normal and Machado-Joseph disease brains.
Fujigasaki H; Uchihara T; Koyano S; Iwabuchi K; Yagishita S; Makifuchi T; Nakamura A; Ishida K; Toru S; Hirai S; Ishikawa K; Tanabe T; Mizusawa H
Exp Neurol; 2000 Oct; 165(2):248-56. PubMed ID: 10993685
[TBL] [Abstract][Full Text] [Related]
7. Non-expanded polyglutamine proteins in intranuclear inclusions of hereditary ataxias--triple-labeling immunofluorescence study.
Uchihara T; Fujigasaki H; Koyano S; Nakamura A; Yagishita S; Iwabuchi K
Acta Neuropathol; 2001 Aug; 102(2):149-52. PubMed ID: 11563629
[TBL] [Abstract][Full Text] [Related]
8. [Polyglutamine-expanded ataxin-3 is degraded by autophagy].
Xiao H; Tang J; Hu Z; Tan J; Tang B; Jiang Z
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2010 Feb; 27(1):23-8. PubMed ID: 20140862
[TBL] [Abstract][Full Text] [Related]
9. Cell cycle arrest enhances the in vitro cellular toxicity of the truncated Machado-Joseph disease gene product with an expanded polyglutamine stretch.
Yoshizawa T; Yamagishi Y; Koseki N; Goto J; Yoshida H; Shibasaki F; Shoji S; Kanazawa I
Hum Mol Genet; 2000 Jan; 9(1):69-78. PubMed ID: 10587580
[TBL] [Abstract][Full Text] [Related]
10. Ectoine alters subcellular localization of inclusions and reduces apoptotic cell death induced by the truncated Machado-Joseph disease gene product with an expanded polyglutamine stretch.
Furusho K; Yoshizawa T; Shoji S
Neurobiol Dis; 2005 Oct; 20(1):170-8. PubMed ID: 16137577
[TBL] [Abstract][Full Text] [Related]
11. [Mechanisms to control degradation of polyglutamine-containing protein].
Nakayama K
Rinsho Shinkeigaku; 2003 Nov; 43(11):906-8. PubMed ID: 15152500
[TBL] [Abstract][Full Text] [Related]
12. Differential susceptibility of cultured cell lines to aggregate formation and cell death produced by the truncated Machado-Joseph disease gene product with an expanded polyglutamine stretch.
Yoshizawa T; Yoshida H; Shoji S
Brain Res Bull; 2001 Oct-Nov 1; 56(3-4):349-52. PubMed ID: 11719271
[TBL] [Abstract][Full Text] [Related]
13. Ataxin-3 protein modification as a treatment strategy for spinocerebellar ataxia type 3: removal of the CAG containing exon.
Evers MM; Tran HD; Zalachoras I; Pepers BA; Meijer OC; den Dunnen JT; van Ommen GJ; Aartsma-Rus A; van Roon-Mom WM
Neurobiol Dis; 2013 Oct; 58():49-56. PubMed ID: 23659897
[TBL] [Abstract][Full Text] [Related]
14. Toward therapeutic targets for SCA3: Insight into the role of Machado-Joseph disease protein ataxin-3 in misfolded proteins clearance.
Li X; Liu H; Fischhaber PL; Tang TS
Prog Neurobiol; 2015 Sep; 132():34-58. PubMed ID: 26123252
[TBL] [Abstract][Full Text] [Related]
15. Full-length expanded ataxin-3 enhances mitochondrial-mediated cell death and decreases Bcl-2 expression in human neuroblastoma cells.
Tsai HF; Tsai HJ; Hsieh M
Biochem Biophys Res Commun; 2004 Nov; 324(4):1274-82. PubMed ID: 15504352
[TBL] [Abstract][Full Text] [Related]
16. Chemical chaperones reduce aggregate formation and cell death caused by the truncated Machado-Joseph disease gene product with an expanded polyglutamine stretch.
Yoshida H; Yoshizawa T; Shibasaki F; Shoji S; Kanazawa I
Neurobiol Dis; 2002 Jul; 10(2):88-99. PubMed ID: 12127147
[TBL] [Abstract][Full Text] [Related]
17. Recruitment and the role of nuclear localization in polyglutamine-mediated aggregation.
Perez MK; Paulson HL; Pendse SJ; Saionz SJ; Bonini NM; Pittman RN
J Cell Biol; 1998 Dec; 143(6):1457-70. PubMed ID: 9852144
[TBL] [Abstract][Full Text] [Related]
18. Machado-Joseph disease/spinocerebellar ataxia type 3.
Paulson H
Handb Clin Neurol; 2012; 103():437-49. PubMed ID: 21827905
[TBL] [Abstract][Full Text] [Related]
19. Compromised mitochondrial complex II in models of Machado-Joseph disease.
Laço MN; Oliveira CR; Paulson HL; Rego AC
Biochim Biophys Acta; 2012 Feb; 1822(2):139-49. PubMed ID: 22037589
[TBL] [Abstract][Full Text] [Related]
20. Polyglutamine-induced neurodegeneration in SCA3 is not mitigated by non-expanded ataxin-3: conclusions from double-transgenic mouse models.
Hübener J; Riess O
Neurobiol Dis; 2010 Apr; 38(1):116-24. PubMed ID: 20079840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
